71 related articles for article (PubMed ID: 26813866)
1. Denosumab-induced hypocalcemia in patients with solid tumors and renal dysfunction: a multicenter, retrospective, observational study.
Nakamura K; Kaya M; Yanagisawa Y; Yamamoto K; Takayashiki N; Ukita H; Nagura M; Sugiue K; Kitajima M; Hirano K; Ishida H; Onoda C; Kobayashi Y; Nakatani E; Odagiri K; Suzuki T
BMC Cancer; 2024 Feb; 24(1):218. PubMed ID: 38360579
[TBL] [Abstract][Full Text] [Related]
2. Reducing the risk of denosumab-induced hypocalcemia in patients with advanced chronic kidney disease: a quality improvement initiative.
Kanagalingam T; Khan T; Sultan N; Cowan A; Thain J; Hoy C; Ledger S; Clemens KK
Arch Osteoporos; 2023 Nov; 18(1):138. PubMed ID: 37985504
[TBL] [Abstract][Full Text] [Related]
3. Denosumab-Associated Severe Hypocalcemia in Dialysis-Dependent Patients.
Schoenmakers I; Fraser WD
JAMA; 2024 Jun; 331(21):1864-1865. PubMed ID: 38717748
[No Abstract] [Full Text] [Related]
4. Denosumab-Associated Severe Hypocalcemia in Dialysis-Dependent Patients-Reply.
Bird ST; Gelperin K; Graham DJ
JAMA; 2024 Jun; 331(21):1865-1866. PubMed ID: 38717783
[No Abstract] [Full Text] [Related]
5. Recurrent severe hypocalcemia following chemotherapy regimen changes in advanced breast cancer: two case reports.
Yanase Y; Bando H; Sato R; Matsuo T; Ueda A; Okazaki M; Hashimoto S; Iguchi-Manaka A; Hara H
J Med Case Rep; 2024 Mar; 18(1):150. PubMed ID: 38523303
[TBL] [Abstract][Full Text] [Related]
6. Denosumab administration for bone metastases from solid tumors: a retrospective cross-sectional study.
Mizuta K; Oshiro H; Katsuki R; Tsuha Y; Aoki Y; Tome Y; Nishida K
BMC Cancer; 2023 Oct; 23(1):999. PubMed ID: 37853409
[TBL] [Abstract][Full Text] [Related]
7. Bone-targeting agents in major solid tumour metastases: a multinational cohort study.
Kim JH; Shen CY; Au PC; Baek YH; Cheung CL; Chung WP; Kleinman NJ; Lam TC; Liao TC; Lin TC; Shin JY; Sing CW; Wong ICK; Lai EC
BMJ Support Palliat Care; 2024 Jan; 13(e3):e1064-e1073. PubMed ID: 35177433
[TBL] [Abstract][Full Text] [Related]
8. Denosumab Decreases Epicardial Adipose Tissue Attenuation in Dialysis Patients with Secondary Hyperparathyroidism and Low Bone Mass.
Chen CL; Liou ES; Wu MT
Cardiorenal Med; 2024; 14(1):113-122. PubMed ID: 38325352
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of denosumab treatment for lung metastasis secondary to proximal humerus chondroblastoma.
Samargandi R; Bernard M; Miquelestorena-Standley E; Nail LRL
Saudi Med J; 2024 Jun; 45(6):633-638. PubMed ID: 38830665
[TBL] [Abstract][Full Text] [Related]
10. An unresectable osteoblastoma of the axis controlled with denosumab.
Yamaga K; Kuwamoto S; Tanishima S; Yamashita H; Asano N; Matsushita M; Akahori K; Osaki M; Hisaoka M; Nagashima H
J Orthop Sci; 2024 Jan; 29(1):379-383. PubMed ID: 35469739
[No Abstract] [Full Text] [Related]
11. Adjuvant trastuzumab for triple-positive breast cancer with chronic renal failure: A case report and review of literature.
En W; Long Y
Medicine (Baltimore); 2024 Jan; 103(1):e36278. PubMed ID: 38181290
[TBL] [Abstract][Full Text] [Related]
12. Denosumab-induced hypocalcemia in patients treated with dialysis: an avoidable complication?
Lloret MJ; Jørgensen HS; Evenepoel P
Clin Kidney J; 2024 Mar; 17(3):sfae048. PubMed ID: 38500493
[No Abstract] [Full Text] [Related]
13. Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis.
Yerram P; Kansagra S; Abdelghany O
J Oncol Pharm Pract; 2017 Apr; 23(3):179-184. PubMed ID: 26830549
[TBL] [Abstract][Full Text] [Related]
14. Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?
Sidhu HK
Dent Update; 2015 Jun; 42(5):436-8, 440. PubMed ID: 26964445
[TBL] [Abstract][Full Text] [Related]
15. High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors.
Kinoshita Y; Arai M; Ito N; Takashi Y; Makita N; Nangaku M; Shinoda Y; Fukumoto S
Endocr J; 2016 May; 63(5):479-84. PubMed ID: 26860123
[TBL] [Abstract][Full Text] [Related]
16. A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.
Laskowski LK; Goldfarb DS; Howland MA; Kavcsak K; Lugassy DM; Smith SW
J Med Toxicol; 2016 Sep; 12(3):305-8. PubMed ID: 26987988
[TBL] [Abstract][Full Text] [Related]
17. Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies.
Thongprayoon C; Acharya P; Acharya C; Chenbhanich J; Bathini T; Boonpheng B; Sharma K; Wijarnpreecha K; Ungprasert P; Gonzalez Suarez ML; Cheungpasitporn W
Osteoporos Int; 2018 Aug; 29(8):1737-1745. PubMed ID: 29713798
[TBL] [Abstract][Full Text] [Related]
18. Use of denosumab in a dialysis patient with bone metastases from breast cancer and hepatorenal polycystic disease: a case report.
Quiroga García V; Cirauqui Cirauqui B; Tobey Robaina L; López Sisamon D; Hardy-Werbin M; Blanca AB; Margelí Vila M
Anticancer Drugs; 2016 Jun; 27(5):464-9. PubMed ID: 26813866
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
